Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H -A. Becker

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Diabetes, Obesity & Metabolism|June 27, 2007
Insulin glulisine: a faster onset of action compared with insulin lisproT Heise, L Nosek, H Spitzer, et al.
Diabetes Care|April 28, 2005
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulinKlaus Rave, Susanne Bott, Lutz Heinemann, et al.
Diabetes, Obesity & Metabolism|March 22, 2008
Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjectsR H A Becker, A D Frick, L Teichert, et al.
Diabetes Care|October 25, 2012
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetesGeremia B Bolli, Annke D Hahn, Ronald Schmidt, et al.
Acta Diabetologica|January 24, 2004
Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusionH E Scholtz, S G Pretorius, D H Wessels, et al.
Diabetes, Obesity & Metabolism|November 27, 2014
Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetesM Shiramoto, T Eto, S Irie, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Diabetes, Obesity & Metabolism|June 27, 2007
Insulin glulisine: a faster onset of action compared with insulin lisproT Heise, L Nosek, H Spitzer, et al.
Diabetes Care|April 28, 2005
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulinKlaus Rave, Susanne Bott, Lutz Heinemann, et al.
Diabetes, Obesity & Metabolism|March 22, 2008
Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjectsR H A Becker, A D Frick, L Teichert, et al.
Diabetes Care|October 25, 2012
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetesGeremia B Bolli, Annke D Hahn, Ronald Schmidt, et al.
Acta Diabetologica|January 24, 2004
Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusionH E Scholtz, S G Pretorius, D H Wessels, et al.
Diabetes, Obesity & Metabolism|November 27, 2014
Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetesM Shiramoto, T Eto, S Irie, et al.
Pageof 4